ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1636

Long-term Renal Survival of Patients with LN by Renal Response Status in the Toronto Lupus Cohort

Murray Urowitz1, Mary E. Georgiou2, Jiandong Su3, Anne MacKinnon3, Yulia Green4, Kerry Gairy2, Roger A Levy5 and Patricia C. Juliao6, 1University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, 2GlaxoSmithKline, Value Evidence and Outcomes, Brentford, United Kingdom, 3University of Toronto Lupus Program, Schroeder Arthritis Institute, University Health Network, Division of Rheumatology, Toronto, ON, Canada, 4GlaxoSmithKline, Clinical Development, Brentford, United Kingdom, 5GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, 6GlaxoSmithKline, Value Evidence and Outcomes, Collegeville, PA

Meeting: ACR Convergence 2022

Keywords: Epidemiology, Lupus nephritis, Renal

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: Abstracts: Epidemiology and Public Health I: Risk Factors and Outcomes

Session Type: Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: Approximately 40% of adult patients with SLE develop LN, which can lead to end-stage kidney disease (ESKD).1 Renal response is used in clinical trials as a measure of treatment efficacy in patients with LN; however, there are various definitions of renal response and limited evidence to support whether it accurately predicts long-term renal outcomes. A study using data from the Hopkins Lupus Cohort showed that a real-world modified version of the primary efficacy renal response (mPERR; without requirement of tapering of oral steroid therapy) endpoint of the BLISS-LN study (NCT01639339) accurately predicted long-term renal outcomes.2

This study primarily assessed the association between mPERR status at 2 years (2Y) post-biopsy-proven LN and long-term renal survival (no ESKD or death) among patients with LN from the University of Toronto Lupus Cohort (TLC) database, a prospective, longitudinal cohort of patients with SLE.

Methods: This retrospective observational study (GSK Study 212866) used data from eligible adult patients with biopsy-proven class III, IV, V, III/V, or IV/V LN within the TLC. Patients were followed up from 2Y post-biopsy until censoring. Primary and secondary endpoints included the associations of mPERR status with long-term renal survival, and survival without moderate/severe chronic kidney disease (CKD; defined as absence of ≥2 new, consecutive eGFR < 60 ml/min/1.73 m2 occurrences recorded ≥3 months apart).

Patients were classified as mPERR or no mPERR at 2Y post-biopsy. mPERR was defined as proteinuria ≤0.7 g/24 h and an estimated glomerular filtration rate (eGFR) ≤20% below biopsy value or ≥60 ml/min/1.73 m2. Long-term renal survival was defined as the absence of ESKD (defined as eGFR < 30 ml/min/1.73 m2, dialysis, or transplant) or death, assessed during the follow-up period. Kaplan-Meier plots and log-rank tests were used to compare survival outcomes by mPERR status.

Results: In total, 179 patients were included in the ESKD analysis, with a mean (standard deviation) age of 34.2 (11.3) years at biopsy; class IV LN was the most frequent (n=66, 36.9%). At 2Y post-biopsy, 128 (71.5%) patients achieved mPERR, while 51 (28.5%) did not. Achieving mPERR was associated with an increased likelihood of long-term renal survival versus not achieving mPERR (p=0.0130; Figure 1).

For long-term survival without moderate/severe CKD analysis, 154/179 patients were included; 25 had moderate/severe CKD prior to 2Y post-biopsy and were excluded. At 2Y post-biopsy, 110 (71.4%) patients achieved mPERR, while 44 (28.6%) did not. Achieving mPERR was associated with an increased likelihood of long-term survival without moderate/severe CKD versus not achieving mPERR (p< 0.0001; Figure 2).

Conclusion: Achieving mPERR at 2Y post-biopsy was associated with improved long-term renal survival and survival without moderate/severe CKD. This adds to the existing body of evidence that mPERR status is a suitable predictor of long-term renal outcomes within different patient populations and validates the need for sustained response to therapy.

Funding: GSK

References
1Mahajan A, et al. Lupus. 2020;29:1011–20
2Petri M, et al. Arthritis Rheumatol. 2020;72 (suppl 10)

Supporting image 1

Figure 1. Probability of long-term renal survival among patients who achieved mPERR (red) and those who did not achieve mPERR (blue) at 2Y post-biopsy.

Follow-up period is the time after mPERR assessment (year 0 in the figure is 2Y post-biopsy). Beyond year 15, patient sample sizes were small so should be interpreted with caution.

Supporting image 2

Figure 2. Probability of long-term survival without moderate/severe CKD among patients who achieved mPERR (red) and those who did not achieve mPERR (blue) at 2Y post-biopsy.

Follow-up period is the time after mPERR assessment (year 0 in the figure is 2Y post-biopsy). Beyond year 15, patient sample sizes were small so should be interpreted with caution.


Disclosures: M. Urowitz, None; M. Georgiou, GlaxoSmithKline (GSK); J. Su, None; A. MacKinnon, None; Y. Green, GlaxoSmithKline (GSK); K. Gairy, GlaxoSmithKline (GSK); R. Levy, GlaxoSmithKline (GSK); P. Juliao, GlaxoSmithKline (GSK).

To cite this abstract in AMA style:

Urowitz M, Georgiou M, Su J, MacKinnon A, Green Y, Gairy K, Levy R, Juliao P. Long-term Renal Survival of Patients with LN by Renal Response Status in the Toronto Lupus Cohort [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/long-term-renal-survival-of-patients-with-ln-by-renal-response-status-in-the-toronto-lupus-cohort/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-renal-survival-of-patients-with-ln-by-renal-response-status-in-the-toronto-lupus-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology